HRS 5041
Alternative Names: HRS-5041Latest Information Update: 30 Aug 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 23 Aug 2024 Jiangsu HengRui Medicine plans a phase I/II trial for Prostate cancer and Adenocarcinoma (Combination therapy, Late-stage disease) in China (PO) in September 2024 (NCT06568094),
- 22 Aug 2024 Atridia Pty plans a phase I trial in healthy Caucasian male (In Volunteers) in Australia in September 2024 (PO) (NCT06559007)
- 14 Jul 2023 Phase-I clinical trials in Prostate cancer (Metastatic disease, Late-stage disease, In adults, In the elderly, Hormone refractory) in China (PO) (NCT05942001) (Jiangsu Hengrui Pharmaceuticals pipeline, July 2023)